Cees J. van Groeningen

Ziekenhuis Amstelland

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Herbert M. Pinedo

Amsterdam University Medical Centers

Godefridus J. Peters

Amsterdam University Medical Centers

Giuseppe Giaccone

Jacobi Medical Center

Emile J. Laurensse

University of Amsterdam

C.L. van der Wilt

University Medical Center Utrecht

Sybren L. Meijer

Amsterdam University Medical Centers

Kees Smid

Vrije Universiteit Amsterdam

J.M.G.H. van Riel

Elisabeth-TweeSteden Ziekenhuis

Helen Gall

Vanderbilt University Medical Center

Robert Mauritz

Amsterdam UMC Location VUmc

Cooperative Institutions

Vrije Universiteit Amsterdam

Amsterdam UMC Location VUmc

University of Amsterdam

Amsterdam University Medical Centers

Texas Oncology

The Netherlands Cancer Institute

The University of Texas MD Anderson Cancer Center

University Medical Center

GEICAM – Spanish Breast Cancer Group

Radboud University Nijmegen

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Electroporation Therapy in Soft Tissue Sarcoma: A Potentially Effective Novel Treatment

Sarcoma (2006)

Remco de Bree Bernard M. Tijink Cees J. van Groeningen C. René Leemans

Purpose. Examination of the potential of electroporation therapy (EPT) in a patient with metastatic soft tissue sarcoma. Patient. A 24-year-old male who underwent extensive resection and postoperative radiotherapy for a malignant peripheral nerve sheath tumor in the right infratemporal fossa with intracranial extension and invasion of the maxillary sinus and mandible had a recurrence in the scar of his craniotomy for which he was initially treated with doxorubicin. After discontinuation of doxorubicin he developed a metastatic mass at the same site for which he was treated with electroporation therapy. Method. The subcutaneous metastasis was infiltrated with bleomycin and electroporated. Results. Gradually the tumor became increasingly necrotic and demarcated from surrounding tissue. After 10 weeks no tumor was seen anymore. The wound healed secondarily. Discussion. Intralesional bleomycin followed by EPT is potentially effective, well tolerated, and easy to perform in well accessible soft tissue sarcoma sites.

10.1155/srcm/2006/85234

Cite

Citations (15)

The Role of Deoxycytidine Kinase in Gemcitabine Cytotoxicity

Advances in experimental medicine and biology (2002)

C.L. van der Wilt Judith R. Kroep Andries M. Bergman Willem J.P Loves Enrique Álvarez

Deoxycytidine kinase

10.1007/0-306-46843-3_56

Cite

Citations (27)

Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: Enzyme activity and inhibition by 5-fluoro-2′-deoxyuridine-5′-monophosphate

European Journal of Cancer and Clinical Oncology (1991)

Godefridus J. Peters Cees J. van Groeningen Emile J. Laurensse Herbert M. Pinedo

Intestinal mucosa

Deoxyuridine

Mechanism of Action

10.1016/0277-5379(91)90512-c

Cite

Citations (39)

Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data.

Pharmaceutical Research (1987)

Godefridus J. Peters Cees J. van Groeningen Emile J. Laurensse I Kraal A. Leyva

Cytidine

Uracil

Bolus (digestion)

10.1023/a:1016410817898

Cite

Citations (36)

Chemotherapy in advanced soft tissue sarcomas

Cancer treatment and research (1989)

Jaap Verweij Cees J. van Groeningen Herbert M. Pinedo

10.1007/978-1-4613-1757-9_6

Cite

Citations (7)

Thymidylate Synthase Inhibition Induces P53 Dependent and Independent Cell Death

Advances in experimental medicine and biology (2002)

Harold H.J. Backus D. Wouters C.L. van der Wilt Catherina M. Kuiper Cees J. van Groeningen

10.1007/0-306-46843-3_59

Cite

Citations (6)

Early Intervention with Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of Quality-of-Life Results of a Multicenter, Randomized, Controlled Trial Compared with Population Normative Data

The Oncologist (2006)

Jorine H. Savonije Cees J. van Groeningen Lars W. Wormhoudt Giuseppe Giaccone

Learning Objectives After completing this course, the reader will be able to: Discuss the benefit of anemia correction with epoetin alfa therapy on improving quality of life in patients with cancer receiving chemotherapy.Relative to population norms, describe the quality-of-life results of a prospective, randomized study in which cancer patients with baseline Hb levels ≤12.1 g/dl received epoetin alfa or best supportive care.Explain how patients with cancer and mild-to-moderate anemia have impaired quality of life relative to the normal population and experience significant and clinically meaningful quality-of-life improvements with earlier epoetin alfa treatment. CME Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.com

Epoetin alfa

10.1634/theoncologist.11-2-197

Cite

Citations (8)

Polymorphisms in the Enhancer Region of the Thymidylate Synthase Gene Are Associated with Thymidylate Synthase Levels in Normal Tissues but Not in Malignant Tissues of Patients with Colorectal Cancer

Clinical Colorectal Cancer (2009)

Robert Mauritz Elisa Giovannetti Inès J. Beumer Kees Smid Cees J. van Groeningen

10.3816/ccc.2009.n.024

Cite

Citations (21)

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

New England Journal of Medicine (2009)

Jolien Tol Miriam Koopman Annemieke Cats C. J. Rodenburg G.J. Creemers

Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer.We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or the same regimen plus weekly cetuximab (CBC regimen, 377 patients). The primary end point was progression-free survival. The mutation status of the KRAS gene was evaluated as a predictor of outcome.The median progression-free survival was 10.7 months in the CB group and 9.4 in the CBC group (P=0.01). Quality-of-life scores were lower in the CBC group. The overall survival and response rates did not differ significantly in the two groups. Treated patients in the CBC group had more grade 3 or 4 adverse events, which were attributed to cetuximab-related adverse cutaneous effects. Patients treated with cetuximab who had tumors bearing a mutated KRAS gene had significantly decreased progression-free survival as compared with cetuximab-treated patients with wild-type-KRAS tumors or patients with mutated-KRAS tumors in the CB group.The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life. Mutation status of the KRAS gene was a predictor of outcome in the cetuximab group. (ClinicalTrials.gov number, NCT00208546.)

Regimen

Progression-free survival

Chemotherapy regimen

10.1056/nejmoa0808268

Cite

Citations (1,320)

Potentiation of 5-Fluorouracil Induced Inhibition of Thymidylate Synthase in Human Colon Tumors by Leucovorin is Dose Dependent

Advances in experimental medicine and biology (1993)

Godefridus J. Peters Klaas Hoekman Cees J. van Groeningen C.L. van der Wilt Kees Smid

Bolus (digestion)

10.1007/978-1-4615-2960-6_126

Cite

Citations (11)